Abstract
Childhood allergic diseases, including asthma, rhinitis and eczema, are prevalent conditions that share strong genetic and environmental components. Diagnosis relies on clinical history and measurements of allergen-specific IgE. We hypothesized that a multi-omics model could accurately diagnose childhood allergic disease. We show that nasal DNA methylation has by far the strongest predictive power to diagnose childhood allergy, surpassing blood DNA methylation, genetic risk scores, and environmental factors. DNA methylation at only three nasal CpG sites classifies allergic disease in Dutch children, with an area under the curve (AUC) of 0.86. This was replicated in US Hispanic children (AUC 0.82). DNA methylation at these CpGs additionally detects allergic multimorbidity and symptomatic IgE sensitization. Using nasal single-cell RNA-sequencing data, we map these three CpG sites to reflect the influx of T cells and macrophages that contribute to allergic inflammation. Our study offers a simple, non-invasive diagnostic test for childhood allergy.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The PIAMA study was supported by The Netherlands Organization for Health Research and Development; The Netherlands Organization for Scientific Research; Lung Foundation of the Netherlands (with methylation studies supported by AF 4.1.14.001); The Netherlands Ministry of Spatial Planning, Housing, and the Environment; The Netherlands Ministry of Health, Welfare, and Sport; and the Ubbo Emmius Foundation. Yang Li was supported by an ERC Starting Grant (948207) and the Radboud University Medical Centre Hypatia Grant (2018) for Scientific Research. Cancan Qi was supported by a grant from the China Scholarship Council. Cheng-Jian Xu was supported by the Helmholtz Initiative and Networking Fund (1800167).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Medical Ethical Committees of the participating institutes approved the study (Utrecht and Groningen METC (Medisch Ethische Toetsings Commissie) protocol number 12-019/K).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵‡ These authors jointly supervised this work: Gerard H. Koppelman, Cheng-Jian Xu
Data Availability
All data produced in the present study will be deposited in the European Genome-phenome Archive (EGA) upon publication.